---
layout: default
title: Levosimendan
parent: 僅模型預測 (L5)
nav_order: 80
evidence_level: L5
indication_count: 0
---

# Levosimendan
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# LEVOSIMENDAN: Evaluation Incomplete — No TxGNN Predictions Available

## One-Sentence Summary

Levosimendan is an inodilator / calcium sensitizer used clinically for acute decompensated heart failure in multiple European markets.
The current Evidence Pack contains **no TxGNN repurposing predictions** for this compound,
and two blocking data gaps — missing package-insert warnings and missing mechanism-of-action data — prevent a standard repurposing evaluation from being completed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Acute decompensated heart failure (known clinical use; no authorisation registered in Sweden) |
| Predicted New Indication | No predictions available in this Evidence Pack |
| TxGNN Prediction Score | — |
| Evidence Level | — (cannot be determined) |
| Sweden Market Status | Not marketed (0 authorisations) |
| Number of Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Evaluation Can Be Completed

Three independent blockers prevent this Evidence Pack from proceeding through the standard repurposing pipeline:

**1. No TxGNN predictions (`predicted_indications: []`)**
The model has not yet generated candidate indications for DB00922. Without a scored disease target, there is no repurposing hypothesis to evaluate, and all downstream sections (clinical-trial evidence, literature evidence, mechanism plausibility) cannot be populated.

**2. Missing package-insert safety data (Data Gap DG001 — Blocking)**
Warnings and contraindications from the TFDA (or equivalent authority) have not been retrieved. This is classified as a *Blocking* gap: it prevents the mandatory S1 safety screening step and means no safety section can be written.

**3. Missing mechanism of action (Data Gap DG002 — High)**
Without confirmed MOA data from DrugBank, the mechanistic plausibility argument that anchors the "Why is this prediction reasonable?" section cannot be constructed.

---

## Sweden Market Information

No authorisations are registered in Sweden for LEVOSIMENDAN. There is no licensing table to display.

---

## Safety Considerations

All safety fields (key warnings, contraindications, drug interactions) returned no data in this Evidence Pack. Please refer to the approved package insert for safety information once it has been retrieved.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for LEVOSIMENDAN is structurally incomplete: the TxGNN model has not produced a repurposing prediction, and two data gaps (missing safety data and missing MOA) have been flagged as Blocking / High severity. No repurposing recommendation can be made until these inputs are available.

**To proceed, the following is needed:**

- [ ] **Re-run TxGNN inference** for DB00922 and populate `predicted_indications` with at least one scored disease candidate
- [ ] **Retrieve TFDA (or EMA/FIMEA) package insert** — extract warnings and contraindications to resolve DG001 *(Blocking)*
- [ ] **Query DrugBank API** for MOA data to resolve DG002 *(High)* — enables mechanistic plausibility analysis
- [ ] **Re-run DDI lookup** once MOA is confirmed — current query returned `not_found`
- [ ] **Confirm Sweden regulatory pathway** — if Simdax or a generic is approved elsewhere in the EU, assess mutual-recognition applicability

Once these four items are resolved, re-submit the updated Evidence Pack for a full L1–L5 evaluation.
---

